{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:15:39Z","timestamp":1791396939765,"version":"4.3.3"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.beha.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T02:32:20Z","timestamp":1550543540000},"page":"98-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["TP53 and therapy-related myeloid neoplasms"],"prefix":"10.1016","volume":"32","author":[{"given":"Jae","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2019.02.009_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2019.02.009_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1309\/NQ3PMV4U8YV39JWJ","article-title":"Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant","volume":"127","author":"Singh","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.009_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2019.02.009_bib4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.009_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-015-0139-z","article-title":"TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases","volume":"8","author":"Ok","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.beha.2019.02.009_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.beha.2019.02.009_bib7","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJM199310283291807","article-title":"Clinical implications of the p53 tumor-suppressor gene","volume":"329","author":"Harris","year":"1993","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.beha.2019.02.009_bib8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2019.02.009_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2017-02-763086","article-title":"Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy","volume":"130","author":"Prokocimer","year":"2017","journal-title":"Blood"},{"issue":"7540","key":"10.1016\/j.beha.2019.02.009_bib10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.beha.2019.02.009_bib11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.1995.13.4.1009","article-title":"Implications of the p53 tumor-suppressor gene in clinical oncology","volume":"13","author":"Chang","year":"1995","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2019.02.009_bib12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"6630","key":"10.1016\/j.beha.2019.02.009_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/387299a0","article-title":"Regulation of p53 stability by Mdm2","volume":"387","author":"Kubbutat","year":"1997","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.beha.2019.02.009_bib14","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1002\/j.1460-2075.1996.tb00919.x","article-title":"MDMX: a novel p53-binding protein with some functional properties of MDM2","volume":"15","author":"Shvarts","year":"1996","journal-title":"EMBO J"},{"issue":"6630","key":"10.1016\/j.beha.2019.02.009_bib15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.beha.2019.02.009_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/j.1460-2075.1993.tb05678.x","article-title":"mdm2 expression is induced by wild type p53 activity","volume":"12","author":"Barak","year":"1993","journal-title":"EMBO J"},{"issue":"6381","key":"10.1016\/j.beha.2019.02.009_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.beha.2019.02.009_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.beha.2019.02.009_bib19","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.beha.2019.02.009_bib20","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2012-03-419622","article-title":"A novel hierarchical prognostic model of AML solely based on molecular mutations","volume":"120","author":"Grossmann","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.02.009_bib21","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Rucker","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2019.02.009_bib22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2019.02.009_bib23","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/leu.2016.74","article-title":"High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS\/AML cohort","volume":"30","author":"Goel","year":"2016","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.beha.2019.02.009_bib24","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/sj.onc.1210294","article-title":"Transcription regulation by mutant p53","volume":"26","author":"Weisz","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.beha.2019.02.009_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ng0593-42","article-title":"Gain of function mutations in p53","volume":"4","author":"Dittmer","year":"1993","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.beha.2019.02.009_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0092-8674(84)90532-4","article-title":"Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene","volume":"38","author":"Wolf","year":"1984","journal-title":"Cell"},{"issue":"36","key":"10.1016\/j.beha.2019.02.009_bib27","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.1038\/sj.onc.1210337","article-title":"p63 and p73 in human cancer: defining the network","volume":"26","author":"Deyoung","year":"2007","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.beha.2019.02.009_bib28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/ng.2270","article-title":"Detectable clonal mosaicism and its relationship to aging and cancer","volume":"44","author":"Jacobs","year":"2012","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.beha.2019.02.009_bib29","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/ng.2271","article-title":"Detectable clonal mosaicism from birth to old age and its relationship to cancer","volume":"44","author":"Laurie","year":"2012","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.beha.2019.02.009_bib30","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMc1500684","article-title":"Clonal hematopoiesis and blood-cancer risk","volume":"372","author":"Genovese","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2019.02.009_bib31","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.beha.2019.02.009_bib32","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2019.02.009_bib33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2015-10-677021","article-title":"Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML","volume":"127","author":"Wong","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2019.02.009_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.009_bib35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.beha.2019.02.009_bib36","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2019.02.009_bib37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2007-11-126508","article-title":"MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility","volume":"112","author":"Ellis","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2019.02.009_bib38","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.beha.2019.02.009_bib39","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.18632\/oncotarget.3460","article-title":"Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes","volume":"6","author":"Devillier","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.beha.2019.02.009_bib40","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/leu.2008.143","article-title":"Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype","volume":"22","author":"Haferlach","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2019.02.009_bib41","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2011-02-339721","article-title":"Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation","volume":"118","author":"Fang","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2019.02.009_bib42","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2013-12-544957","article-title":"Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"123","author":"Middeke","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2019.02.009_bib43","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"Dohner","year":"2018","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.beha.2019.02.009_bib44","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2019.02.009_bib45","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMc1616062","article-title":"Decitabine in TP53-mutated AML","volume":"376","author":"Montalban-Bravo","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2019.02.009_bib46","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1038\/bcj.2016.60","article-title":"An open-label phase I dose-finding study of APR-246 in hematological malignancies","volume":"6","author":"Deneberg","year":"2016","journal-title":"Blood Cancer J"},{"issue":"29","key":"10.1016\/j.beha.2019.02.009_bib47","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.009_bib48","series-title":"ASH annual conference","article-title":"Abstract CT068: phase Ib\/II combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)","author":"Sallman","year":"2018"},{"issue":"5","key":"10.1016\/j.beha.2019.02.009_bib49","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026245","article-title":"Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: progress and challenges","volume":"7","author":"Wang","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"46","key":"10.1016\/j.beha.2019.02.009_bib50","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1038\/onc.2011.185","article-title":"Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3","volume":"30","author":"Aziz","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.beha.2019.02.009_bib51","series-title":"ASH annual conference","article-title":"4066 phase 1\/1b study of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, as monotherapy or in combination with cytarabine for the treatment of relapsed\/refractory AML and advanced MDS with TP53 wild-type","author":"Sallman","year":"2018"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T21:33:56Z","timestamp":1553722436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692619300106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1521692619300106"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.02.009","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 and therapy-related myeloid neoplasms","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}